Table 1: Baseline characteristics of all four studies.
Author
& Year |
Sample
Size |
Mean
age (years / SD) |
Ultrasound
device |
Contrast
agent |
Immunosuppresive
treatment (number received) |
Grzelak
et al., 2013 [7] |
102 |
47
(12.5) |
GE
Vivid 7, 3.5MHz probe |
2.4ml
SonoVue IV |
Steroids
(103), CyA or Tac (103) MMF (103). |
Fischer
et al., 2005 [8] |
6 |
36
(11.6) |
Aplio
80, Toshiba 3.5MHz transducer |
1.6ml
SonoVue IV bolus & 5ml NaCl |
- |
Fischer
et al., 2006 [9] |
7 |
41
(11) |
Aplio
80, Toshiba 3.5MHz transducer |
2.4ml
SonoVue IV bolus & 5ml NaCl |
Tac
(3), CyA (4), MMF(5) |
Grzelak
et al., 2012 [6] |
16 |
48.3
(9.9) |
GE
Vivid 7, 3.5MHz probe |
2.4ml
SonoVue IV |
Steroids
(16), CyA or Tac (16), MMF(16) |
CyA: Ciclosporin A; Tac: Tacrolimus; MMF: Mycophenolate Mofetil.